Significant barriers exist that impede the translation of innovative and important ideas to the clinic. The Reach Grant seeks to remove one of these barriers by providing support for important preclinical hypothesis-driven research projects that are necessary to move a study from the preclinical arena into a clinical trial. Thus, the goal of this award is to support translational studies that will result in a phase 1 and/or 2 clinical trial, two to three years from the project start date. Examples of appropriate research projects include but aren’t limited to, completing INDenabling studies, providing requisite preclinical data for clinical trial development, or perhaps through the validation of biomarkers that will enable selection of the correct patients for entry into new clinical trials.
Deadline: April 11, 2023
• Applicant institutions must be based in the United States or Canada. Applicants need not be United States citizens. Funds must be granted to nonprofit institutions or organizations.
• Applicants must have an MD, PhD, or MD/PhD or equivalent and be appointed as faculty (or equivalent) at an academic institution.
• Applicants must have a demonstrated track record of pediatric cancer research with experience in translational research.
• Multiple investigator applications that bring together pairs or teams of researchers with complementary expertise are encouraged.
The requested budget should be in proportion to the scope of the proposed project and should be for direct costs of $250,000 USD or below over 2 years. A maximum of $125,000 in total costs may be requested per year.
